Previous 10 | Next 10 |
Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021. Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021. Studies are complementary and address both dose duration and disease stage variations. Data from b...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With so much enthusiasm baked into the equities sector, many investors undoubtedly feel that now is a time to consider a risk-off profile. Frankly, I agree with these folks. That said, we’re coming off the (hopefully...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While it may seem like “meme-stock mania” is over, several of these names are still up triple digits this year. In fact, much-maligned meme stocks are not losing steam as the more than 10 million members of R...
Sorrento Therapeutics (NASDAQ: SRNE) didn't have a case of the Mondays at all. The company's stock zoomed 6.7% higher today on very encouraging news from across the pond. After U.S. market hours on Friday, Sorrento divulged that the U.K.'s Medicines and Healthcare Products Regul...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sorrento Therapeutics (NASDAQ: SRNE ) is a stock that’s on fire today. Investors in SRNE stock have seen gains of 6% at the time of writing on heavy volume. More than double the average daily volume of shares h...
loops7/E+ via Getty Images Sorrento Therapeutics (SRNE) has risen ~3.5% in extended trading after announcing that the company received regulatory clearance in the U.K. to start a Phase 2 efficacy trial for its COVI-DROPS product candidate. The decision by the Medicines and...
Large Phase 2 efficacy trial cleared to start in the United Kingdom in newly diagnosed SARS-CoV-2 infected patients. COVI-DROPS is administered by intranasal drops and the antibody is active against the original SARS-CoV-2 virus, as well as the UK/Alpha and India/Delta variants, cur...
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies using the Sofusa Lymphatic Drug Delivery System (S-LDDS) technology acro...
APTO is presenting new data at EHA21 for its Btk inhibitor, Luxeptinib. The data could be a catalyst event (up or down) for this stock. There's a lot of competition for non-covalent Btk inhibitors in blood cancers. For further details see: Aptose: Cancer Trial Catalyst A...
Photo by AlexanderFord/E+ via Getty Images Sorrento Therapeutics (SRNE) announced that HER2-ADC, A166 an experimental breast cancer therapy developed in partnership with Kelun-Biotech indicated a “better safety profile” and “potentially better efficacy” in a P...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...